Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study

EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR

Read more at globenewswire.com